Griffith University


Cancer Therapeutics (CTx)

CTx is underpinned by AUD148M in public / private partnership funds to drive the best small-molecule cancer research to cancer drug candidates. In collaboration with CTx, Discovery Biology performs assay development, high throughput screening and lead optimization for candidate cancer targets.

Medicines for Malaria Venture (MMV)

MMV is a not-for-profit, public-private partnership that was established as a foundation in Switzerland in 1999. Their mission is to reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating delivery of new, effective and affordable antimalarial drugs. On behalf of MMV, Discovery Biology has screened millions of compounds for anti-malarial activity and is currently developing new high throughput screening assays.

Drugs for Neglected Diseases initiative (DNDi)

DNDi is a collaborative, patients’ needs-driven, non-profit drug research and development organization that is developing new treatments for malaria, visceral leishmaniasis, sleeping sickness (human African trypanosomiasis), and Chagas disease.  Discovery Biology has previously collaborated with DNDi in developing a high throughput screening assay for human african trypanosomiasis.


As the world’s largest research-based pharmaceutical company, Pfizer’s diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines. Discovery Biology has performed numerous high throughput screening campaigns on behalf of Pfizer.